興森科技(002436.SZ):擬對全資子公司廣州科技增資11.47億元
格隆匯2月8日丨興森科技(002436.SZ)公佈,公司於2022年2月8日召開了第六屆董事會第八次會議,審議通過了《關於對全資子公司增資的議案》。廣州興森快捷電路科技有限公司(簡稱“廣州科技”)為公司全資子公司,此次公司擬將廣州科技的註冊資本金由約人民幣8.53億元增加至人民幣20億元,增資資金主要用於廣州科技生產運營。
此次增資金額約為人民幣11.47億元,資金來源於廣州科技的未分配利潤及公司的自有資金(其中,廣州科技截至2020年12月31日經審計的未分配利潤約為人民幣8.69億元,具體以增資時實際數據為準)。此次增資完成後,公司仍持有廣州科技100%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.